Alembic Pharmaceuticals is currently trading at Rs. 1219.95, up by 35.50 points or 3.00% from its previous closing of Rs. 1184.45 on the BSE.
The scrip opened at Rs. 1180.25 and has touched a high and low of Rs. 1221.55 and Rs. 1180.25 respectively. So far 7750 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1254.80 on 29-Jul-2024 and a 52 week low of Rs. 707.50 on 31-Oct-2023.
Last one week high and low of the scrip stood at Rs. 1250.50 and Rs. 1031.05 respectively. The current market cap of the company is Rs. 23863.75 crore.
The promoters holding in the company stood at 69.61%, while Institutions and Non-Institutions held 19.79% and 10.60% respectively.
Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Acitretin Capsules USP, 10 mg, 17.5 mg, and 25 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Soriatane Capsules, 10 mg, 17.5 mg, and 25 mg, of Stiefel Laboratories, Inc. (Stiefel). Acitretin capsules are indicated for the treatment of severe psoriasis in adults.
Acitretin Capsules USP, 10 mg, 17.5 mg, and 25 mg have an estimated market size of $21 million for twelve months ending June 2024 according to IQVIA. The company has a cumulative total of 212 ANDA approvals (184 final approvals and 28 tentative approvals) from USFDA.
Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1808.50 |
Dr. Reddys Lab | 1342.45 |
Cipla | 1472.45 |
Lupin | 2147.55 |
Zydus Lifesciences | 973.90 |
View more.. |